<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="09cdd46f-eae9-4faa-b3b3-67fcd71b62ff"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use LEVOTHYROXINE SODIUM INJECTION safely and effectively. <br/>See full prescribing information for LEVOTHYROXINE SODIUM INJECTION.<br/>
      <br/>LEVOTHYROXINE SODIUM injection, for intravenous use <br/>Initial U.S. Approval: 2002 </title>
   <effectiveTime value="20250317"/>
   <setId root="08f4b1f8-6807-47e7-bef8-8d1972aa0557"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="608775388" root="1.3.6.1.4.1.519.1"/>
            <name>Fresenius Kabi USA, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="023648251" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-885" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-890" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-895" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-885" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-890" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-895" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="8f49f022-17be-4f1d-afd2-8238d60b402e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250317"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-885" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levothyroxine Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="ug" value="20"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9J765S329G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Levothyroxine sodium</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Levothyroxine</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Levothyroxine Sodium Anhydrous</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="023C2WHX2V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Tromethamine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5WR8N145C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Iodide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-885-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180529"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180529"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210632" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-890" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levothyroxine Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="ug" value="40"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9J765S329G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Levothyroxine sodium</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Levothyroxine</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Levothyroxine Sodium Anhydrous</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="023C2WHX2V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Tromethamine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5WR8N145C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Iodide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-890-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180529"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180529"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210632" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-895" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levothyroxine Sodium</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levothyroxine Sodium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="ug" value="100"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="9J765S329G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Levothyroxine sodium</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q51BO43MG4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Levothyroxine</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="054I36CPMN" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Levothyroxine Sodium Anhydrous</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="023C2WHX2V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Tromethamine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5WR8N145C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Iodide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-895-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180529"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180529"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210632" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="616e0e7f-bb76-4233-a18b-329ac091dbde"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Thyroid hormones, including Levothyroxine Sodium Injection, should not be used for the treatment of obesity or for weight loss.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Larger doses may produce serious or even life threatening manifestations of toxicity. (<linkHtml href="#s13">6</linkHtml>,<linkHtml href="#s33">10</linkHtml>)</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS</paragraph>
                        <paragraph>
                           <content styleCode="bold">Thyroid hormones, including Levothyroxine Sodium Injection, should not be used for the treatment of obesity or for weight loss.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Larger doses may produce serious or even life threatening manifestations of toxicity. (<linkHtml href="#s13">6</linkHtml>,<linkHtml href="#s33">10</linkHtml>)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="9555e3b4-169e-4da2-98ea-9eb8848ce9e7"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Levothyroxine Sodium Injection is indicated for the treatment of myxedema coma. </paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levothyroxine Sodium Injection is L-thyroxine (T4) indicated in adult patients for the treatment of myxedema coma. (<linkHtml href="#s2">1</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>Not recommended as a substitute for oral levothyroxine sodium because the relative bioavailability of Levothyroxine Sodium Injection to oral levothyroxine sodium has not been established and there is a risk of inaccurate dose conversion. (<linkHtml href="#s2">1</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="2721a98d-ae17-46e9-ae3a-0bbc523ff2aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <paragraph>Not recommended as a substitute for oral levothyroxine sodium because the relative bioavailability of Levothyroxine Sodium Injection to oral levothyroxine sodium has not been established and there is a risk of inaccurate dose conversion. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="40337a3e-00d6-4297-a3ba-7bf4715ce746"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Consider the age, general physical condition, cardiac risk factors, and clinical severity of myxedema and duration of myxedema symptoms when determining dosages of Levothyroxine Sodium Injection. (<linkHtml href="#s5">2.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Start with lower doses in elderly patients and in patients with underlying cardiovascular disease. (<linkHtml href="#s5">2.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>The recommended loading dose is 300 mcg to 500 mcg administered intravenously. (<linkHtml href="#s5">2.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>The recommended maintenance dose is 50 mcg to 100 mcg administered intravenously daily until the patient can tolerate oral therapy. (<linkHtml href="#s5">2.1</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Administer Levothyroxine Sodium Injection intravenously at a rate not to exceed 100 mcg per minute. (<linkHtml href="#s6">2.2</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Do not add Levothyroxine Sodium Injection to intravenous fluids. (<linkHtml href="#s6">2.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s5">
                     <id root="fa424eb9-a0bc-423c-a0dd-3b3dcb3b46dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosage </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Consider the age, general physical condition, cardiac risk factors, and clinical severity of myxedema and duration of myxedema symptoms when determining the starting and maintenance dosages of Levothyroxine Sodium Injection. </item>
                           <item>
                              <caption>•</caption>Start with lower doses in elderly patients and in patients with underlying cardiovascular disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#s32">8.5</linkHtml>)].</content>
                           </item>
                           <item>
                              <caption>•</caption>The recommended loading dose of Levothyroxine Sodium Injection is 300 mcg to 500 mcg administered intravenously. </item>
                           <item>
                              <caption>•</caption>The recommended maintenance dose of Levothyroxine Sodium Injection is 50 mcg to 100 mcg administered intravenously daily until the patient can tolerate oral therapy. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="e04c5f5f-15d3-4507-a6dc-a893dffef952"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Administration Instructions </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Administer Levothyroxine Sodium Injection as an intravenous injection at a rate not to exceed 100 mcg per minute. </item>
                           <item>
                              <caption>•</caption> Do not add Levothyroxine Sodium Injection to intravenous fluids. </item>
                           <item>
                              <caption>•</caption>Inspect Levothyroxine Sodium Injection visually prior to injection. It should appear clear and colorless, solution free of visible particulates. Do not use if particulate matter or coloration is seen. </item>
                           <item>
                              <caption>•</caption>Discard any unused portion. </item>
                        </list>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="3b70afa4-7130-4511-bbae-94776450ecee"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Levothyroxine Sodium Injection is clear, colorless solution supplied as: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>100 mcg per 5 mL (20 mcg per mL) single-dose vial </item>
                     <item>
                        <caption>•</caption>200 mcg per 5 mL (40 mcg per mL) single-dose vial </item>
                     <item>
                        <caption>•</caption>500 mcg per 5 mL (100 mcg per mL) single-dose vial </item>
                  </list>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>100 mcg per 5 mL (20 mcg per mL) single-dose vial </item>
                           <item>
                              <caption>•</caption>200 mcg per 5 mL (40 mcg per mL) single-dose vial </item>
                           <item>
                              <caption>•</caption>500 mcg per 5 mL (100 mcg per mL) single-dose vial (<linkHtml href="#s7">3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s8">
               <id root="f67f27ae-0448-4b5e-9421-2cecbfef1609"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Uncorrected adrenal insufficiency <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s11">5.2</linkHtml>)]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Uncorrected adrenal insufficiency. (<linkHtml href="#s8">4</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="caef27a3-8a6e-4ee8-895d-b1976790ece5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease:</content> Overtreatment may cause arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death, particularly in patients with cardiovascular disease and in elderly patients. Start with lower doses in elderly patients and in patients with underlying cardiovascular disease and monitor patients after administration (<linkHtml href="#s10">5.1</linkHtml>). </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency:</content> Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment (<linkHtml href="#s11">5.2</linkHtml>). </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Worsening of Diabetic Control:</content> May worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control (<linkHtml href="#s12">5.3</linkHtml>). </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s10">
                     <id root="e81be8a5-00c5-45dc-a346-69393e59f1e6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease </title>
                     <text>
                        <paragraph>Overtreatment with Levothyroxine Sodium Injection may cause arrhythmias, tachycardia, myocardial ischemia and infarction, or worsening of congestive heart failure and death, particularly in patients with cardiovascular disease and in elderly patients. Start with lower doses in elderly patients and in patients with underlying cardiovascular disease and monitor patients after administration of Levothyroxine Sodium Injection for cardiac adverse reactions. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="1e60060a-e69b-473e-86b7-61266ecc101e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency </title>
                     <text>
                        <paragraph>Chronic autoimmune thyroiditis, which can lead to myxedema coma, may occur in association with other autoimmune disorders such as adrenal insufficiency. Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency <content styleCode="italics">[see Contraindications (<linkHtml href="#s8">4</linkHtml>)].</content> Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with Levothyroxine Sodium Injection. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="763562af-8fc9-4892-88df-65845dbd40a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Worsening of Diabetic Control </title>
                     <text>
                        <paragraph>Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s17">7.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="1ce99f52-e7aa-4505-bc4a-01acc24cb3ab"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>Adverse reactions associated with levothyroxine are primarily those of hyperthyroidism due to therapeutic overdosage <content styleCode="italics">[see <content styleCode="underline">Warnings and Precautions (</content>
                        <linkHtml href="#s9">5</linkHtml>
                        <content styleCode="underline">)</content>, <content styleCode="underline">Overdosage (</content>
                        <linkHtml href="#s33">10</linkHtml>
                        <content styleCode="underline">)</content>]</content>. They include the following: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">General:</content> fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Central nervous system:</content> headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Musculoskeletal:</content> tremors, muscle weakness, muscle spasm </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Cardiovascular:</content> palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Respiratory:</content> dyspnea </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Gastrointestinal:</content> diarrhea, vomiting, abdominal cramps, elevations in liver function tests </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Dermatologic:</content> flushing, rash </item>
                  </list>
                  <paragraph>Seizures have been reported rarely with the institution of levothyroxine therapy. </paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions associated with Levothyroxine Sodium Injection are primarily those of hyperthyroidism due to therapeutic overdosage: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating, headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia, tremors, muscle weakness, muscle spasm, palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest, dyspnea, diarrhea, vomiting, abdominal cramps, elevations in liver function tests, flushing, and rash. (<linkHtml href="#s13">6</linkHtml>) </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s14">
                     <id root="0c14ddd1-a4de-4b18-a7da-4b487c9bfd77"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="89365063-04e7-462e-90ed-349a7f4ed3f6"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250317"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., synthesis, secretion, catabolism, protein binding, and target tissue response) that may alter the therapeutic response to Levothyroxine Sodium Injection. (<linkHtml href="#s15">7</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s16">
                     <id root="6c5fe958-4028-4c9e-b556-54e5cc4b28e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics </title>
                     <text>
                        <paragraph>Many drugs affect thyroid hormone pharmacokinetics and metabolism (e.g., synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Injection (see <linkHtml href="#_Reft1a">Tables 1</linkHtml>-<linkHtml href="#_Reft3">3</linkHtml>).</paragraph>
                        <table ID="_Reft1a" width="100%">
                           <caption>Table 1: Drugs That May Alter T<sub>4</sub> and Triiodothyronine (T<sub>3</sub>) Serum Transport Without Effecting Free Thyroxine (FT<sub>4</sub>) Concentration (Euthyroidism) </caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Clofibrate<br/>Estrogen-containing oral contraceptives<br/>Estrogens (oral)<br/>Heroin / Methadone<br/>5-Fluorouracil<br/>Mitotane<br/>Tamoxifen </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>These drugs may increase serum thyroxine-binding globulin (TBG) concentration. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Androgens / Anabolic Steroids<br/>Asparaginase<br/>Glucocorticoids<br/>Slow-Release Nicotinic Acid </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>These drugs may decrease serum TBG concentration. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Potential impact (below): Administration of these agents with levothyroxine results in an initial transient increase in FT<sub>4</sub>. Continued administration results in a decrease in serum T<sub>4</sub> and normal FT<sub>4</sub> and TSH concentrations. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Salicylates (&gt; 2 g/day)<br/>
                                       <br/>
                                       <br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Salicylates inhibit binding of T<sub>4</sub> and T<sub>3</sub> to TBG and transthyretin. An initial increase in serum FT<sub>4</sub> is followed by return of FT<sub>4</sub> to normal levels with sustained therapeutic serum salicylate concentrations, although total T<sub>4</sub> levels may decrease by as much as 30%. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Other drugs:<br/>Carbamazepine<br/>Furosemide (&gt; 80 mg IV)<br/>Heparin<br/>Hydantoins<br/>Non-Steroidal Anti-inflammatory Drugs<br/>- Fenamates </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters. </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_Reft2" width="100%">
                           <caption>Table 2:  Drugs That May Alter Hepatic Metabolism of T<sub>4</sub> (Hypothyroidism) </caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased levothyroxine requirements. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Phenobarbital<br/>Rifampin </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5'-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine. </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_Reft3" width="100%">
                           <caption>Table 3:  Drugs That May Decrease Conversion of T<sub>4</sub> to T<sub>3</sub>
                           </caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T<sub>4</sub> to T<sub>3</sub>, leading to decreased T<sub>3</sub> levels. However, serum T<sub>4</sub> levels are usually normal but may occasionally be slightly increased. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Drug or Drug Class</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Effect</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Beta-adrenergic antagonists<br/>(e.g., Propranolol &gt; 160 mg/day)<br/>
                                       <br/>
                                       <br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>In patients treated with large doses of propranolol (&gt; 160 mg/day), T<sub>3</sub> and T<sub>4</sub> levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. It should be noted that actions of particular beta-adrenergic antagonists may be impaired when the hypothyroid patient is converted to the euthyroid state. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Glucocorticoids<br/>(e.g., Dexamethasone ≥ 4 mg/day)<br/>
                                       <br/>
                                       <br/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Short-term administration of large doses of glucocorticoids may decrease serum T<sub>3</sub> concentrations by 30% with minimal change in serum T<sub>4</sub> levels. However, long-term glucocorticoid therapy may result in slightly decreased T<sub>3</sub> and T<sub>4</sub> levels due to decreased TBG production (See above). </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Other drugs:<br/>Amiodarone </paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients. </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="08c53b42-e527-4053-9cc9-4a26f27202e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Antidiabetic Therapy </title>
                     <text>
                        <paragraph>Addition of levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements. Careful monitoring of glycemic control is recommended. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="caef5492-6201-4560-bbd8-976b64696646"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Oral Anticoagulants </title>
                     <text>
                        <paragraph>Levothyroxine increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="97b39944-1e56-42ac-a762-32cdf4dc78aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Digitalis Glycosides </title>
                     <text>
                        <paragraph>Levothyroxine may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may be decreased when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="b2a725c2-212c-4acf-b4ba-6636d42e7d1a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Antidepressant Therapy </title>
                     <text>
                        <paragraph>Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. Levothyroxine may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on levothyroxine may result in increased levothyroxine requirements. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="3467f617-8a51-46c0-8400-0f794f6d4aba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Ketamine </title>
                     <text>
                        <paragraph>Concurrent use of ketamine and levothyroxine may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="7a83e843-7e7b-4ebb-96c8-8ec027b37b92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7 Sympathomimetics </title>
                     <text>
                        <paragraph>Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="262f0d57-8403-4a83-90dd-a9c7ebbc920f"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>7.8 Drug-Laboratory Test Interactions </title>
                     <text>
                        <paragraph>Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen containing oral contraceptives, and acute intermittent porphyria increase TBG concentrations. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9,000. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s24">
               <id root="392ce70f-fd15-4a85-87f0-31bab1812e21"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250317"/>
               <component>
                  <section ID="s25">
                     <id root="97be891c-6bfe-4144-a2e1-20a14dfe08bc"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <effectiveTime value="20250317"/>
                     <component>
                        <section ID="s26">
                           <id root="bd58e720-14eb-4869-815f-f4cf6caf72da"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no available data with use of Levothyroxine Sodium Injection in pregnant women. The clinical data in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not reported increased rates of major birth defects, miscarriages, or adverse maternal or fetal outcomes <content styleCode="italics">(see <linkHtml href="#ID_cf5dde03-b999-40b0-b974-cb7014649217">Data</linkHtml>).</content> There are risks to the mother and fetus associated with myxedema coma in pregnancy <content styleCode="italics">(see <linkHtml href="#ID_28b625e2-d6e4-4f14-8dde-10ebc0ca14d2">Clinical Considerations</linkHtml>)</content>. Animal reproduction studies have not been conducted with levothyroxine sodium. </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. </paragraph>
                           </text>
                           <effectiveTime value="20250317"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_28b625e2-d6e4-4f14-8dde-10ebc0ca14d2">
                           <id root="e42ce3c9-a265-46ac-a9db-aa4cc343d356"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                              </paragraph>
                              <paragraph>Myxedema coma is a medical emergency which can be fatal, if left untreated. Delaying treatment in pregnant women with myxedema coma increases the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of Levothyroxine Sodium Injection on the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20250317"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_cf5dde03-b999-40b0-b974-cb7014649217">
                           <id root="607412d5-506c-4947-8c29-bf3ff96da9b4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Human Data</content>
                              </paragraph>
                              <paragraph>There is no available data with use of Levothyroxine Sodium Injection in pregnant women. Oral levothyroxine is approved for use as a replacement therapy in hypothyroidism. There is a long experience of oral levothyroxine use in pregnant women that has not reported increased rates of fetal malformations, miscarriages or other adverse maternal or fetal outcomes associated with levothyroxine use in pregnant women.</paragraph>
                           </text>
                           <effectiveTime value="20250317"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s29">
                     <id root="0c60431c-13fa-4a7a-a613-aff94403d74e"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <effectiveTime value="20250317"/>
                     <component>
                        <section ID="s30">
                           <id root="29854e56-ad3d-4ac3-b26c-6b1950be296c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Published studies report that levothyroxine is present in human milk following the administration of oral levothyroxine. However, there is insufficient information to determine the effects of levothyroxine on the breastfed infant and no available information on the effects of levothyroxine on milk production. There is no available data with use of Levothyroxine Sodium Injection in lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for levothyroxine and any potential adverse effects on the breastfed infant from levothyroxine or from the underlying maternal condition. </paragraph>
                           </text>
                           <effectiveTime value="20250317"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="7cdf6ac7-b6e6-48a2-a584-2f699152c7e8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and efficacy of Levothyroxine Sodium Injection have not been established in pediatric patients. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s32">
                     <id root="014ee1a1-98e3-4e05-9edb-a186a0e1bfd9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Because of the increased prevalence of cardiovascular disease among the elderly, initiate Levothyroxine Sodium Injection with lower doses in elderly patients and in patients with underlying cardiovascular disease and closely monitor for cardiac adverse reactions. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.1</linkHtml>) and Warnings and Precautions (<linkHtml href="#s10">5.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s33">
               <id root="55d0e5e6-a2ff-44f8-935a-9d7d31eccc25"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>The signs and symptoms of overdosage are those of hyperthyroidism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s9">5</linkHtml>) and Adverse Reactions (<linkHtml href="#s13">6</linkHtml>)].</content> In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Reduce the Levothyroxine Sodium Injection dose or temporarily discontinue if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient's medical status. </paragraph>
               </text>
               <effectiveTime value="20250317"/>
            </section>
         </component>
         <component>
            <section ID="s34">
               <id root="2927f91a-85a4-4307-872e-876b10b2e221"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Levothyroxine Sodium Injection contains synthetic crystalline levothyroxine (T4) in sodium salt form. Levothyroxine sodium has an empirical formula of C<sub>15</sub>H<sub>10</sub>I<sub>4</sub>NNaO<sub>4</sub>, a molecular weight of 798.85 g/mol (anhydrous), and the following structural formula: </paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Levothyroxine Sodium Injection is a sterile, preservative free, clear, colorless, sterile solution for intravenous administration available as: 100 mcg per 5 mL (20 mcg per mL), 200 mcg per 5 mL (40 mcg per mL), and 500 mcg per 5 mL (100 mcg per mL). Each mL of Levothyroxine Sodium Injection also contains 10 mg Tromethamine, USP; 0.14 mg Sodium Iodide, USP; 6.48 mg Sodium Chloride, USP; and Water for Injection, USP Sodium hydroxide, NF and/or Hydrochloric acid, USP may have been added for pH adjustment (9.5 – 10.8). Levothyroxine Sodium Injection is in single dose clear glass vials. </paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lev19-0002-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="3c1bd7ef-2cfb-4fa0-a51b-018135b3f451"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250317"/>
               <component>
                  <section ID="s36">
                     <id root="b97789c9-ff47-4486-bbb6-22b8b7b65af3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and levothyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. </paragraph>
                        <paragraph>The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s37">
                     <id root="9baea23f-6114-43f9-afc7-86ae4f280d17"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>Levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
               <component>
                  <section ID="s38">
                     <id root="ac934f7f-bb1f-4259-be1e-b2326a953cbb"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <effectiveTime value="20250317"/>
                     <component>
                        <section ID="s39">
                           <id root="1e3a0017-6641-4060-9637-c3e45091a3c9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Distribution</content>
                              </paragraph>
                              <paragraph>Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine binding globulin (TBG), thyroxine binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half life of T4 compared to T3. Protein bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s15">7</linkHtml>)].</content> Thyroid hormones do not readily cross the placental barrier <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s25">8.1</linkHtml>)].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250317"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s40">
                           <id root="2b865905-b234-48eb-9914-3787210883a2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Metabolism</content>
                              </paragraph>
                              <paragraph>T4 is slowly eliminated. The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately eighty percent of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation. </paragraph>
                           </text>
                           <effectiveTime value="20250317"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s41">
                           <id root="c8da6d46-317a-4050-a997-611dfe95c27e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Excretion</content>
                              </paragraph>
                              <paragraph>Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged, where it is hydrolyzed and eliminated in feces as the free hormones. Urinary excretion of T4 decreases with age. </paragraph>
                              <table ID="_Reft1b" width="100%">
                                 <caption>Table 1: Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients </caption>
                                 <col width="18%"/>
                                 <col width="25%"/>
                                 <col width="16%"/>
                                 <col width="16%"/>
                                 <col width="24%"/>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="5" styleCode="Botrule" valign="top">T<sub>4</sub>: Levothyroxine <br/>T<sub>3</sub>: Liothyronine <br/>
                                          <sup>1</sup> 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism. <br/>
                                          <sup>2</sup> Includes TBG, TBPA, and TBA. </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Hormone</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Ratio in Thyroglobulin</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Biologic Potency</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Half-Life (Days)</content>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Toprule " valign="top">
                                          <paragraph>
                                             <content styleCode="bold">Protein Binding</content>
                                             <br/>
                                             <content styleCode="bold">(%)<sup>2</sup>
                                             </content>
                                          </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Lrule Botrule " valign="top">
                                          <paragraph>T<sub>4</sub>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>10 to 20 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>1 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>6 to 8<sup>1</sup>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>99.96 </paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule Lrule " valign="top">
                                          <paragraph>T<sub>3</sub>
                                          </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>1 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>4 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>≤ 2 </paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule " valign="top">
                                          <paragraph>99.5 </paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250317"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s42">
               <id root="d5dff269-e948-43ea-a847-428d05387dcc"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250317"/>
               <component>
                  <section ID="s43">
                     <id root="2b4a6e0b-d508-4980-9a1a-dc510e7c93ee"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of Levothyroxine Sodium Injection. </paragraph>
                     </text>
                     <effectiveTime value="20250317"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s44">
               <id root="cb90ce36-feba-4b4a-bfdd-c3ae088b79c5"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Levothyroxine Sodium Injection is a clear, colorless solution available as follows: </paragraph>
                  <table width="100%">
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Product Code</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Unit of Sale</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Strength</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Each</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>885110</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>NDC 63323-885-10</paragraph>
                              <paragraph>Individually Packaged</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>100 mcg per 5 mL</paragraph>
                              <paragraph>(20 mcg per mL)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>NDC 63323-885-10</paragraph>
                              <paragraph>5 mL</paragraph>
                              <paragraph>Single-Dose Vial</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>886110</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>NDC 63323-895-10</paragraph>
                              <paragraph>Individually Packaged</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>500 mcg per 5 mL</paragraph>
                              <paragraph>(100 mcg per mL)</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>NDC 63323-895-10</paragraph>
                              <paragraph>5 mL</paragraph>
                              <paragraph>Single-Dose Vial</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>887110</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>NDC 63323-890-10</paragraph>
                              <paragraph>Individually Packaged</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>200 mcg per 5 mL</paragraph>
                              <paragraph>(40 mcg per mL)</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>NDC 63323-890-10</paragraph>
                              <paragraph>5 mL</paragraph>
                              <paragraph>Single-Dose Vial</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Protect from light in the original vial in a carton and store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. The unopened vial may be stored for up to 24 hours exposed to indoor lighting outside of the carton. The drug product is preservative free. Discard any unused portion. </paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
                  <paragraph>Lake Zurich, IL 60047 </paragraph>
                  <paragraph>www.fresenius-kabi.com/us </paragraph>
                  <paragraph>451617A </paragraph>
                  <paragraph>Revised: November 2024</paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Fresenius Logo </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="lev19-0002-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s45">
               <id root="a839c315-c4b1-43f9-a346-cfad3ec5ff4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY – Levothyroxine Sodium Injection 5 mL Vial Label</content>
                     <br/>NDC 63323-885-10<br/>
                     <content styleCode="bold">Levothyroxine Sodium</content>
                  </paragraph>
                  <paragraph>Injection<br/>
                     <content styleCode="bold">100 mcg per 5 mL</content>
                  </paragraph>
                  <paragraph>(20 mcg per mL)<br/>For intravenous use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative free.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Single-Dose Vial-</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <renderMultiMedia ID="id454219734" referencedObject="ID_369b0533-125d-45b8-b82e-f27198bec04c"/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="ID_369b0533-125d-45b8-b82e-f27198bec04c">
                     <text>levot-label-01.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s46">
               <id root="9657b848-1c11-4418-8b7c-3f465ff90f86"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY – Levothyroxine Sodium Injection 5 mL Carton Panel</content>
                     <br/>NDC 63323-885-10<br/>
                     <content styleCode="bold">Levothyroxine Sodium</content>
                  </paragraph>
                  <paragraph>Injection<br/>
                     <content styleCode="bold">100 mcg per 5 mL</content>
                  </paragraph>
                  <paragraph>(20 mcg per mL)<br/>For intravenous use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative free.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Single-Dose Vial-</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <paragraph>Rx only<br/>
                     <renderMultiMedia ID="id1224719002" referencedObject="E4E5B0E7-0CE5-49F3-B097-4D0F98118A3B"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="E4E5B0E7-0CE5-49F3-B097-4D0F98118A3B">
                     <text>levot-label-02.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s47">
               <id root="84e59a4f-9e11-452e-a905-31f66f837367"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY – Levothyroxine Sodium Injection 5 mL Vial Label</content>
                     <br/>NDC 63323-895-10<br/>
                     <content styleCode="bold">Levothyroxine Sodium</content>
                  </paragraph>
                  <paragraph>Injection<br/>
                     <content styleCode="bold">500 mcg per 5 mL</content>
                  </paragraph>
                  <paragraph>(100 mcg per mL)<br/>For intravenous use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative free.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Single-Dose Vial-</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <renderMultiMedia ID="id-587009540" referencedObject="ID_9c0e7b86-17f2-40e6-8985-b4cbd90b0961"/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="ID_9c0e7b86-17f2-40e6-8985-b4cbd90b0961">
                     <text>levot-label-03.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s48">
               <id root="b55c958e-fcc3-4308-86ea-e56b2032b963"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY – Levothyroxine Sodium Injection 5 mL Carton Panel</content>
                     <br/>NDC 63323-895-10<br/>
                     <content styleCode="bold">Levothyroxine Sodium</content>
                  </paragraph>
                  <paragraph>Injection<br/>
                     <content styleCode="bold">500 mcg per 5 mL</content>
                  </paragraph>
                  <paragraph>(100 mcg per mL)<br/>For intravenous use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative free.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Single-Dose Vial-</content>
                     <br/>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <paragraph>Rx only </paragraph>
                  <renderMultiMedia ID="id-1674093317" referencedObject="B7DAE8A1-655D-4FBF-BE66-EA6E0FACEAB8"/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="B7DAE8A1-655D-4FBF-BE66-EA6E0FACEAB8">
                     <text>levot-label-04.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s49">
               <id root="3f4d9abf-d406-400e-8d92-28ed3be8ef65"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY – Levothyroxine Sodium Injection 5 mL Vial Label</content>
                     <br/>NDC 63323-890-10<br/>
                     <content styleCode="bold">Levothyroxine Sodium</content>
                  </paragraph>
                  <paragraph>Injection<br/>
                     <content styleCode="bold">200 mcg per 5 mL</content>
                  </paragraph>
                  <paragraph>(40 mcg per mL)<br/>For intravenous use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative free.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Single-Dose Vial-</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <renderMultiMedia ID="id915050049" referencedObject="ID_56e5e4c6-6845-4d57-a293-2fc97674b0d5"/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="ID_56e5e4c6-6845-4d57-a293-2fc97674b0d5">
                     <text>levot-label-05.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s50">
               <id root="2a789870-10da-4d2d-9813-ef5ed9f5160e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY – Levothyroxine Sodium Injection 5 mL Carton Panel</content>
                     <br/>NDC 63323-890-10<br/>
                     <content styleCode="bold">Levothyroxine Sodium</content>
                  </paragraph>
                  <paragraph>Injection<br/>
                     <content styleCode="bold">200 mcg per 5 mL</content>
                  </paragraph>
                  <paragraph>(40 mcg per mL)<br/>For intravenous use. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative free.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5 mL Single-Dose Vial-</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Discard Unused Portion</content>
                  </paragraph>
                  <paragraph>Rx only </paragraph>
                  <renderMultiMedia ID="id-1115286544" referencedObject="F65B6C20-1275-42BF-82B0-3E1F2FF179DD"/>
               </text>
               <effectiveTime value="20250317"/>
               <component>
                  <observationMedia ID="F65B6C20-1275-42BF-82B0-3E1F2FF179DD">
                     <text>levot-label-06.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levot-label-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>